Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …
Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell …
Tarlatamab - Wikipedia
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer. [5] It is a bispecific T-cell engager that …
Tarlatamab-dlle - NCI - National Cancer Institute
Tarlatamab-dlle (Imdelltra) works by bringing healthy T cells (immune cells that help kill cancer cells) and lung cancer cells close together so the T cells can more effectively kill the lung …
Tarlatamab-dlle (intravenous route) - Side effects & uses
Jan 1, 2026 · Tarlatamab-dlle injection is used to treat extensive stage small cell lung cancer (ES-SCLC), which is cancer that has spread throughout the lung or to other parts of the body in …
FDA Grants Full Approval to Lung Cancer Drug Tarlatamab Based …
On November 19, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to the targeted immunotherapy drug tarlatamab (Imdelltra ®) for treating adults with advanced small …
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell
Jun 1, 2023 · Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb-mediated tumor lysis. Herein, we report phase I results of tarlatamab in …
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST …
May 16, 2024 · IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after …
Tarlatamab-dlle (Imdelltra™) : Oncology Times - journals.lww.com
Tarlatamab is a bispecific T-cell engager immunotherapy directed to cancer cells expressing delta-like ligand 3 (DLL3). DLL3 is a protein and inhibits Notch signaling, which is abnormally …
Blood Test Predicts Which Patients with Lung Cancer Will Benefit …
1 day ago · Tarlatamab is an antibody that recruits T cells to cancer cells expressing a specific neuro-endocrine marker called DLL3. Although tarlatamab showed promise in clinical trials, …
FDA Fully Approves New Lung Cancer Drug Tarlatamab
On November 19, 2025, the U.S. Food and Drug Administration (FDA) gave full approval to the drug tarlatamab (brand name Imdelltra) for adults with advanced small cell lung cancer …